Department of Neurology, Huashan Hospital affiliated to Fudan University, Shanghai Shi, China.
Department of Neurology, Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, China.
Stroke Vasc Neurol. 2017 Jun 2;2(3):147-159. doi: 10.1136/svn-2017-000074. eCollection 2017 Sep.
The most effective medical treatment for acute ischaemic stroke (AIS) is to offer intravenous thrombolysis during the ultra-early period of time after the onset. Even based on the Consensus of Chinese Experts on Intravenous Thrombolysis for AIS in 2012 and 2014 Chinese Guidelines on the Diagnosis and Treatment of AIS, the rate of thrombolysis for AIS in China remained around 2.4%, and the rate of intravenous tissue plasminogen activator usage was only about 1.6% in real world. The indication of thrombolysis for AIS has been expanded, and contraindications have been reduced with recently published studies. In order to facilitate the standardisation of treating AIS, improve the rate of thrombolysis and benefit patients who had a stroke, Chinese Stroke Association has organised and developed this scientific statement.
急性缺血性脑卒中（AIS）最有效的治疗方法是在发病后的超早期进行静脉溶栓治疗。即使基于 2012 年和 2014 年中国专家关于 AIS 静脉溶栓治疗的共识以及中国 AIS 诊断和治疗指南，中国 AIS 的溶栓率仍维持在 2.4%左右，实际应用中静脉使用组织型纤溶酶原激活剂的比例仅为 1.6%左右。最近的研究已经扩大了 AIS 溶栓的适应证，减少了禁忌证。为了促进 AIS 的规范化治疗，提高溶栓率，使卒中患者受益，中国卒中学会组织编写了本科学声明。
